RJH Biosciences is a privately held University of Alberta spin-off in Edmonton, Alberta, focused on developing transfection reagents and delivery agents for nucleic acids. The company distributes its products via its website and undertakes projects to create new medical treatments. It has committed to developing a device to enable “Immunotherapy On-the-Go,” a mode of immunotherapy intended to avoid extensive instrumentation and broaden patient access. RJH says this approach would address the high cost and facility requirements of current ex vivo viral-based immunotherapies (the article notes typical treatment costs around $500,000). The company received seed support to advance a Phase I project under the Grand Challenges Explorations initiative. Leadership includes Dr. Hasan Uludag, who commented on the Gates Foundation’s decision to fund the work.

Total raised

$0M

Funding rounds

1

Latest round

Seed

Latest activity

Nov 2019